
Opinion|Videos|May 7, 2024
Evaluating the Impact of Metastatic Breast Cancer on Patients
An expert panel discusses the clinical and economic impact of metastatic breast cancer (mBC) on patients, the prognosis for those with mBC, the three FDA-approved CDK4/6 inhibitors for HR+/HER2- mBC, and the importance of overall survival as a clinical trial endpoint and its relevance to clinical practice.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 Vaccination in Medically Complex Adults
2
The Vaccine Schedule Just Changed Again—Here’s What's Real and What Isn't
3
Testing categories in practice — clinical conversations
4
Why Increasing Uptake of Kidney-Protective Drugs Requires a Team
5




































































































